These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
552 related articles for article (PubMed ID: 18075464)
21. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Terra SG; Hamilton KK; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hill JA; Aranda JM; Yarandi HN; Johnson JA Pharmacogenet Genomics; 2005 Apr; 15(4):227-34. PubMed ID: 15864115 [TBL] [Abstract][Full Text] [Related]
22. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure. Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865 [TBL] [Abstract][Full Text] [Related]
23. [Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure]. Yu WP; Lou M; Deng B; Song HM; Wang HB Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Sep; 34(9):776-80. PubMed ID: 17217681 [TBL] [Abstract][Full Text] [Related]
24. Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. Forleo C; Sorrentino S; Guida P; Romito R; De Tommasi E; Iacoviello M; Pitzalis M J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):589-95. PubMed ID: 17667029 [TBL] [Abstract][Full Text] [Related]
25. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114 [TBL] [Abstract][Full Text] [Related]
26. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254 [TBL] [Abstract][Full Text] [Related]
27. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014 [TBL] [Abstract][Full Text] [Related]
28. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140 [TBL] [Abstract][Full Text] [Related]
29. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278 [TBL] [Abstract][Full Text] [Related]
30. Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy. Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Tange S; Suzuki T; Kurabayashi M J Nucl Med; 2004 Nov; 45(11):1878-84. PubMed ID: 15534058 [TBL] [Abstract][Full Text] [Related]
31. An echocardiographic analysis of the long-term effects of carvedilol on left ventricular remodeling, systolic performance, and ventricular filling patterns in dilated cardiomyopathy. Rahko PS Echocardiography; 2005 Aug; 22(7):547-54. PubMed ID: 16060890 [TBL] [Abstract][Full Text] [Related]
32. Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol: Japanese Chronic Heart Failure (J-CHF) Study. Nagatomo Y; Yoshikawa T; Okamoto H; Kitabatake A; Hori M; J Card Fail; 2015 Mar; 21(3):198-207. PubMed ID: 25528200 [TBL] [Abstract][Full Text] [Related]
33. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. Rusconi P; Gómez-Marín O; Rossique-González M; Redha E; Marín JR; Lon-Young M; Wolff GS J Heart Lung Transplant; 2004 Jul; 23(7):832-8. PubMed ID: 15261177 [TBL] [Abstract][Full Text] [Related]
34. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919 [TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. Del Sindaco D; Pulignano G; Cioffi G; Tarantini L; Di Lenarda A; De Feo S; Opasich C; Minardi G; Giovannini E; Leggio F J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):675-82. PubMed ID: 17700396 [TBL] [Abstract][Full Text] [Related]
36. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S; Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332 [TBL] [Abstract][Full Text] [Related]
37. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Kurum T; Tatli E; Yuksel M Tex Heart Inst J; 2007; 34(1):52-9. PubMed ID: 17420794 [TBL] [Abstract][Full Text] [Related]
38. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure. Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Rhodes J; Margossian R; Darras BT; Colan SD; Jenkins KJ; Geva T; Powell AJ Pediatr Cardiol; 2008 Mar; 29(2):343-51. PubMed ID: 17885779 [TBL] [Abstract][Full Text] [Related]
40. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]